Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 2.22% 92.00 198,559 15:57:48
Bid Price Offer Price High Price Low Price Open Price
91.00 93.00 92.00 91.00 91.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.74 -4.60 -4.30 192
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:52 O 9,526 92.20 GBX

Polarean Imaging (POLX) Latest News

More Polarean Imaging News
Polarean Imaging Investors    Polarean Imaging Takeover Rumours

Polarean Imaging (POLX) Discussions and Chat

Polarean Imaging Forums and Chat

Date Time Title Posts
10/6/202113:16Polarean Imaging PLC1,007

Add a New Thread

Polarean Imaging (POLX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-11 15:29:5392.209,5268,782.97O
2021-06-11 15:21:2691.511,1001,006.62O
View all Polarean Imaging trades in real-time

Polarean Imaging (POLX) Top Chat Posts

DateSubject
12/6/2021
09:20
Polarean Imaging Daily Update: Polarean Imaging Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 90p.
Polarean Imaging Plc has a 4 week average price of 90p and a 12 week average price of 61.90p.
The 1 year high share price is 98.60p while the 1 year low share price is currently 24.50p.
There are currently 209,073,166 shares in issue and the average daily traded volume is 589,454 shares. The market capitalisation of Polarean Imaging Plc is £192,347,312.72.
04/6/2021
07:19
moontheloon: Polarean Imaging PLC Final ResultsSource: UK Regulatory (RNS & others)TIDMPOLXRNS Number : 7908APolarean Imaging PLC04 June 2021Polarean Imaging Plc("Polarean" or the "Company")Final Results for the Year Ended 31 December 2020Notice of Annual General MeetingPolarean Imaging plc (AIM: POLX), the medical - imaging technology company, with an investigational drug - device combination product for magnetic resonance imaging (MRI), announces its audited final results for the year ended 31 December 2020 .In addition, Polarean confirms that the Annual Report and Accounts for the year ended 31 December 2020, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy are now available on the Company's website ( http://www.polarean-ir.com/content/investors/annual-reports.asp ) and will be posted to shareholders shortly.Polarean's AGM will be held at 2500 Meridian Parkway, Suite 175, Durham, NC 27713, USA at 2pm BST / 9am EST on 13 July 2021.Highlights-- Positive top-line results from the Phase III clinical trials using hyperpolarised (129) Xenon gas, where both trials met their primary endpoint-- Raised GBP8.4 million (gross), including a GBP2.2 million subscription from new strategic investor Bracco Imaging S.p.A. ("Bracco")-- Appointment of Jonathan Allis as Non-Executive Chairman -- Appointment of Cyrille Petit as Non-Executive Director and representative of Bracco -- Completion of a pre-New Drug Application ("NDA") meeting with the United States Food and Drug Administration ("FDA") -- Acceptance of the NDA for review by the FDA, with a target Prescription Drug User Fee Act ("PDUFA") action date of 5 October 2021-- Net cash of US$6.3 million as of 31 December 2020 Post-period end-- Raised GBP27 million gross proceeds in an oversubscribed financing, including continued support of strategic investors, Bracco Imaging S.p.A and Nukem Isotopes GmbH as well as institutional investor Amati AIM VCT plc, joined by several new UK and US institutional investors.-- Appointment of Chuck Osborne, Chief Financial Officer, to the Board -- Completion of Mid-Cycle Review of NDA submission with FDA -- Publication of first peer reviewed COVID research by Professor Fergus Gleeson at the University of Oxford-- Additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia in Vancouver, Canada.Richard Hullihen, CEO of Polarean, commented: "It has been a strong year for Polarean, and we have achieved some significant milestones during the period beginning with the positive readout of our Phase III clinical trials in early 2020. This was followed quickly by a successful placing and subscription in April 2020, and a further oversubscribed fundraise in March 2021 which was needed to fund sales and marketing expenses to build the commercial team and infrastructure, to support ongoing clinical trial, regulatory and medical affairs costs, to support the continued investment in research and development and to provide additional working capital and for general corporate purposes."We have made significant Board changes to reflect our progress and we're very excited to have a target PDUFA date from the FDA. On behalf of the whole Board, I would like to thank our employees and shareholders for their ongoing support, and we look forward to further positive updates throughout the rest of the year."This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.Enquiries:
27/5/2021
08:44
4053777: This will blow above ASOS record share price / on Aim ? Hold for gold :)
14/5/2021
11:15
loglorry1: It's in the UK. It's not a POLX market and I very much doubt the NHS would buy even one machine. My friend who works in radiology at a big teaching hospital says that it would be far too cutting edge. POLX is all about tier 1 US hospitals for a good while yet.
10/5/2021
07:45
moontheloon: Polarean Imaging PLC New system orderSource: UK Regulatory (RNS & others)TIDMPOLXRNS Number : 9961XPolarean Imaging PLC10 May 2021Polarean Imaging Plc("Polarean" or the "Company")New System OrderPolarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that it has received an additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia ("UBC"). This is the second system installation at UBC, following the original order in November 2019 which was initially installed at BC Children's Hospital ("BC Children's") while construction was carried out on its intended original site at St. Paul's.As with the original system, this new unit will continue to support UBC's pulmonary disease research programme using hyperpolarised gas imaging. BC Children's is a major paediatric research and teaching hospital, and is the most well-known facility in the province for dealing in juvenile health.Richard Hullihen, CEO of Polarean, said: "We value our long-standing relationship with UBC, a globally recognised research group, and we are excited that they are adding an additional Polariser system to expand their research into the clinical applications of this emerging and much needed technology. We are also pleased to be able to continue to expand our paediatric research cluster, which also includes Cincinnati Children's Hospital Medical Center and Toronto SickKids Hospital. "
30/4/2021
13:04
adorling: The potential here (only for LTH’s of course) is that POLX could become the de facto imaging choice for pulmonary, respiratory and oncology imaging which will be worth £billions worldwide. IMO we are looking at a truly great technology Company with the potential to become a FTSE 100 Company within 4-5 years if not sooner if we are not taken out which is likely of course. This is wholly dependent on the FDA Licence being granted on or before the 5th October (less than 6 months away). Given the success of the phase 3 trials compared to X-Ray and the consultative meetings with the FDA with POLX Rapporteurs to ensure all submissions requirements are fully met I cannot see the outcome being anything other than positive and have added several times this past month to build a significant shareholding.
24/4/2021
19:30
mavern: Some excellent coverage on Justin Waites weekend podcast from 20m 45s to 23 minutes - He says “Share price will start rising way ahead of expected FDA approval in early October” and “Polarean estimate they can do 25 institutions per year for the next 4 years. JW did conservative estimate of just 15 institutions per year which would give a market cap of £1B by 2027”. That’s 7 x current market cap assuming no further dilution. hxxps://audioboom.com/posts/7851726-the-weekend-podcast
09/4/2021
12:10
74tom: Nice posts W T Tutte, haven't posted on the same board as you since the debacle over at TWD, now THAT was a messed up placing! Providing FDA approval is achieved, I'll be surprised if Bracco don't attempt to buy POLX in the next few years before they get too big. I don't think it'll be on the cheap at all and from current levels we'll all do very well. So much of the hard work has been done now, it truly feels like a steal at £140m cap. Will POLX ever list on NASDAQ? Richard did seem to hint at this in the presentation & it would undoubtedly boost the price... presumably timing wise this would be post FDA approval to raise growth capital?
22/2/2021
08:57
gregb: IG spread bets now requires 100% margin on POLX and many more companies. Perhaps this is having an effect on the share price?
20/6/2020
19:31
hedgehog 100: POLX also featured in a new Vox Markets video yesterday: "Polarean Imaging, Bezant Resources and Paul Hill Justin Waite Vox Markets Podcast with Justin Waite 13:14, 19th June 2020 ... Richard Hullihen, Chief Executive Officer of Polarean Imaging (POLX) discusses the highlights from their final results and talks about the outlook over the next twelve months. Polarean, Inc. are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs. The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion. ..." HTTP://www.voxmarkets.co.uk/articles/polarean-imaging-bezant-resources-and-paul-hill-0b823a2 Here are a few extracts (not quoted verbatim): • POLX's technology is the tool that's been missing in pulmonary medicine. • The existing technology struggles to elucidate pulmonary operation. • POLX's technology is obviously needed so much for COVID-19. • Passing the phase III clinical trials was the biggest achievement this year: a major milestone: unambigious success - couldn't be happier re. • FDA review timing from submission to approval: ten months, + 2 months for the Hatch Waxman (exclusivity) request. • There is some chance that the FDA approval process may finish sooner in the current COVID-19 environment. • POLX will also be looking at the possibility of an expedited FDA review. • Research users will inform and drive this expedited review request. • The vaccines and anti-viral sides of COVID-19 are being speeded up, so the diagnostics side should also be speeded up. • The next big milestone will be the FDA application submission. • POLX also has new orders to announce shortly, as soon as they are papered up. • Three good reasons to add POLX to a watchlist? i. POLX's technology is the ideal solution to a huge unmet need in medicine. ii. POLX's technology is all derisked. About US$60M. has been spent commercialising it. iii. Great management team and board with specialist expertise in the field.
20/6/2020
17:00
hedgehog 100: A new POLX video interview was posted on Proactive Investors yesterday: "Polarean Imaging in commercial launch mode for its lung function scanner Andrew Scott 07:18 Fri 19 Jun 2020 Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas MRI. By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function." Here are a few extracts (not quoted verbatim): • The pre-NDA meeting went pretty much as POLX expected. • No delays encountered re. Q3 FDA submission plan. • POLX's drug-device combination is being managed by the drug side of the FDA. • POLX are also seeking a FDA regulatory grant of market exclusivity in the US. • POLX are still selling & installing research equipment - they have an active pipeline - they'll be making a couple of announcements on that in due course. • POLX have non-research target customers for when FDA approval received. • POLX are already preparing for non-research commercial launch. • POLX are excited to be bringing pulmonary medicine in the US into the 21st. century.
Polarean Imaging share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
POLX
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 15:34:15